Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812390 | PMC |
| http://dx.doi.org/10.1136/esmoopen-2017-000318 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ROLE OF ANDROGEN RECEPTOR-TARGETED AGENTS IN LOCALIZED PROSTATE CANCER.
Acta Clin Croat
October 2022
University Hospitals Bristol NHS Foundation Trust, Marlborough Street, Bristol BS13NU, UK.
Anti-androgen therapy continues to be a basic pilar of treatment for both localized and metastatic prostate cancer. The advent of new generation of androgen receptor targeted agents (ARTA) transformed the care of patients with advanced disease. After such a success, the steps were taken to incorporate a new generation of ARTAs into the treatment landscape of localized prostate cancer.
View Article and Find Full Text PDFDuplicated network meta-analysis in advanced prostate cancer: a case study and recommendations for change.
Syst Rev
December 2022
MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, Unversity College London, 90 High Holborn, London, WC1V 6LJ, UK.
Background: Research overlap and duplication is a recognised problem in the context of both pairwise and network systematic reviews and meta-analyses. As a case study, we carried out a scoping review to identify and examine duplicated network meta-analyses (NMAs) in a specific disease setting where several novel therapies have recently emerged: hormone-sensitive metastatic prostate cancer (mHSPC).
Methods: MEDLINE and EMBASE were systematically searched, in January 2020, for indirect or mixed treatment comparisons or network meta-analyses of the systemic treatments docetaxel and abiraterone acetate in the mHSPC setting, with a time-to-event outcome reported on the hazard-ratio scale.
What is the impact of targeted therapies given within phase I trials on the cognitive function of patients with advanced cancer: a mixed-methods exploratory study conducted in an early clinical trials unit.
BMJ Open
November 2022
Faculty of Health Sciences, University of Southampton, Southampton, UK.
Article Synopsis
- The study aims to investigate cognitive toxicity in patients with advanced cancer participating in phase I clinical trials of new therapies, highlighting that subjective side effects, particularly cognitive changes, are often underreported.
- It employs a mixed-methods approach, using both quantitative cognitive assessments and qualitative semi-structured interviews at multiple time points post-treatment to capture the patient experience comprehensively.
- The research has received ethical approval and seeks to bring attention to unmet needs in patient care, potentially improving awareness and support for cognitive side effects during novel cancer therapies.
Combination therapy in metastatic hormone-sensitive prostate cancer: is three a crowd?
Ther Adv Med Oncol
March 2022
Monash University, Level 2, 5 Arnold Street, Box Hill, Melbourne, VIC 3128, Australia.
The mainstay of treatment for metastatic prostate cancer is androgen deprivation therapy (ADT). Outcomes with ADT are variable but control of hormone-sensitive prostate cancer (HSPC) can often be achieved for many years. Death from prostate cancer is usually due to the development of escape variants able to survive and proliferate in the setting of castrate levels of serum androgens (metastatic castration-resistant prostate cancer, mCRPC).
View Article and Find Full Text PDFEstrogen receptor β and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate.
Proc Natl Acad Sci U S A
March 2021
Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, TX 77204;
Knockout of ERβ in the mouse leads to nuclear expression of epidermal growth factor receptor (EGFR) in the prostate. To examine whether ERβ plays a similar role in the human prostate, we used four cohorts of men: 1) a Swedish cohort of normal prostates and PCa (prostate cancer) of different Gleason grades; 2) men with benign prostatic hyperplasia (BPH) treated with the 5α-reductase inhibitor, finasteride, and finasteride together with the ERβ agonists, soy isoflavones; 3) men with PCa above Gleason grade 4 (GG4), treated with ADT (androgen deprivation therapy) and abiraterone (AA), the blocker of androgen synthesis for different durations; and 4) men with GG4 PCa on ADT or ADT with the AR (androgen receptor) blocker, enzalutamide, for 4 mo to 6 mo. In men with BPH, finasteride treatment induced EGFR nuclear expression, but, when finasteride was combined with isoflavones, EGFR remained on the cell membrane.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!